After Hours
$
54.19
Change
-0.09 -0.17%
Volume
Volume 1,168
Sep 21, 2023, 4:24 p.m.
Quotes are delayed by 20 min
Today's close
$ 55.20
$ 54.28
Change
-0.92 -1.67%
Day low
Day high
$54.26
$55.01

52 week low
52 week high
$36.91
$57.82

Market cap
$139.78B
Average volume
1.26M
P/E ratio
15.22
Rev. per Employee
$494,994
EPS
3.57
Dividend
N/A
Div yield
2.53%
Ex dividend date
5/26/22
MarketWatch News on SNY
-
'This Is Not a Covid Vaccine Company,' Moderna CEO Says
- Barron's Online
-
Madrigal Pharmaceuticals shares fall after new CEO named
- Eleanor Laise
-
Novo Nordisk's Wegovy Helped Heart-Failure Patients. What's Next?
- Barron's Online
-
Pfizer maternal RSV vaccine gets FDA approval
- Eleanor Laise
-
Tylenol Litigation Could Be a Headache for Kenvue
- Barron's Online
-
Amazon Pharmacy launches automatic coupons for $35 insulin
- Eleanor Laise
-
CDC Recommends New Sanofi, AstraZeneca Shot to Prevent RSV in Babies
- Barron's Online
-
CDC panel says babies should get new drug that prevents RSV
- Associated Press
-
Microsoft, Alphabet, Meta Platforms and More
- Barron's Online
-
FDA approves Sanofi and AstraZeneca infant RSV vaccine
- Eleanor Laise
-
A Drug for Itchy Dogs Costs $1,200. Why Is the Human Equivalent $43,000?
- Barron's Online
-
GSK, Pfizer RSV Vaccines Get Tepid Endorsment
- Barron's Online
-
GSK Stock Climbs on Zantac Settlement
- Barron's Online
- Loading more headlines...
Analyst Ratings
-
Analysts See a 9.5% Upside for SNY Stock over the Next Year
- MarketRealist.com
-
Analysts’ Recommendations for Valeant in June
- MarketRealist.com
Other News on SNY
-
J&J Revamps Drug Research, Plots Medical Device Deals
- The Wall Street Journal Interactive Edition
-
FDA Approves RSV Vaccine to Pass Protection From Mother to Child
- The Wall Street Journal Interactive Edition
-
Venture Capitalist Seeks to Spur Drug Development for Rare Autoimmune Disease
- The Wall Street Journal Interactive Edition
-
Biogen’s New Boss Is Delivering, but Stock Isn’t Pricing It in Yet
- The Wall Street Journal Interactive Edition
-
FDA Approves First RSV Drug to Protect All Infants
- The Wall Street Journal Interactive Edition
-
Sanofi Wins Supreme Court Patent Dispute With Amgen
- The Wall Street Journal Interactive Edition
-
J&J Prices Consumer Unit IPO at $22 a Share
- The Wall Street Journal Interactive Edition
-
FDA Approves GSK’s RSV Vaccine for Older Adults
- The Wall Street Journal Interactive Edition
-
J&J Consumer-Health Unit’s Listing to Test IPO Market
- The Wall Street Journal Interactive Edition
-
- The Wall Street Journal Interactive Edition
-
Amgen Seeks to Monopolize Nature
- The Wall Street Journal Interactive Edition
-
Regeneron, Sanofi Look for Billions From COPD Drug
- The Wall Street Journal Interactive Edition
-
First Republic Bank, T-Mobile, Credit Suisse: Stocks That Defined the Week
- The Wall Street Journal Interactive Edition
-
Diabetes Drug Giant Sanofi Cuts Insulin Prices by Up to 78%
- The Wall Street Journal Interactive Edition
-
Novo Nordisk to Slash Insulin Prices by Up to 75%
- The Wall Street Journal Interactive Edition
-
Pfizer Agrees to Buy Seagen for $43 Billion
- The Wall Street Journal Interactive Edition
-
Pfizer Overpays for Seagen, but Who’s Counting
- The Wall Street Journal Interactive Edition
-
Regeneron Borrows From Big Pharma Playbook
- The Wall Street Journal Interactive Edition
-
Brandes Investment Comments on Sanofi
- GuruFocus.com
-
Brandes 4th-Quarter Letter: The State of Value Investing
- GuruFocus.com
- Loading more headlines...
Press Releases on SNY
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com